MedTrace Logo

Safety and Efficacy of NAFT900 in Children With Tinea Capitis

NCT02658292 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-09-09

No results posted yet for this study

Summary

A Double-Blind, Randomized, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of NAFT-900 in Children Aged 6 to \< 13 Years with Tinea Capitis

Conditions

  • Tinea Capitis

Interventions

DRUG

Naftifine hydrochloride foam, 3%

Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks

DRUG

Vehicle

Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks

Sponsors & Collaborators

  • Merz North America, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Kuligowski, MD · Merz North America, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2016-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02658292 on ClinicalTrials.gov